Savara Inc Depreciation
Savara Inc (SVRA) reported Depreciation of $100.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-30.
Discontinued › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2022-03-30
- Savara Inc depreciation for the quarter ending 2018-12-31 was $139.00K, a 52.75% increase year-over-year.
- Savara Inc depreciation for the quarter ending 2018-09-30 was $127.00K, a 39.56% increase year-over-year.
- Savara Inc depreciation for the quarter ending 2018-06-30 was $153.00K, a 68.13% increase year-over-year.
- Savara Inc depreciation for the quarter ending 2018-03-31 was $107.00K, a 18.89% increase year-over-year.
- Savara Inc depreciation for fiscal 2021 was $100.00K, a 66.67% decline from fiscal 2020.
- Savara Inc depreciation for fiscal 2020 was $300.00K, a 0.00% change from fiscal 2019.
- Savara Inc depreciation for fiscal 2019 was $300.00K, a 42.97% decline from fiscal 2018.
- Savara Inc depreciation for fiscal 2018 was $526.00K, a 44.90% increase from fiscal 2017.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|---|
| 2021-12-31 | $100.00K 10-K · filed 2022-03-30 | ||||
| 2020-12-31 | $300.00K 10-K · filed 2022-03-30 | ||||
| 2019-12-31 | $300.00K 10-K · filed 2021-03-10 | $311.00K 10-K · filed 2020-03-12 | |||
| 2018-12-31 | $139.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $266.00K derived: sum of 2 quarters · filed 2020-03-12 | $419.00K derived: sum of 3 quarters · filed 2020-03-12 | $526.00K 10-K · filed 2020-03-12 | |
| 2018-09-30 | $127.00K 10-Q · filed 2018-11-07 | $280.00K derived: sum of 2 quarters · filed 2018-11-07 | $387.00K 10-Q · filed 2018-11-07 | $478.00K derived: sum of 4 quarters · filed 2019-03-13 | |
| 2018-06-30 | $153.00K 10-Q · filed 2018-08-09 | $260.00K 10-Q · filed 2018-08-09 | $351.00K derived: sum of 3 quarters · filed 2019-03-13 | $442.00K derived: sum of 4 quarters · filed 2019-03-13 | |
| 2018-03-31 | $107.00K 10-Q · filed 2018-05-09 | $198.00K derived: sum of 2 quarters · filed 2019-03-13 | $289.00K derived: sum of 3 quarters · filed 2019-03-13 | $380.00K derived: sum of 4 quarters · filed 2019-03-13 | |
| 2017-12-31 | $91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $182.00K derived: sum of 2 quarters · filed 2019-03-13 | $273.00K derived: sum of 3 quarters · filed 2019-03-13 | $363.00K 10-K · filed 2019-03-13 | |
| 2017-09-30 | $91.00K 10-Q · filed 2018-11-07 | $182.00K derived: sum of 2 quarters · filed 2018-11-07 | $272.00K 10-Q · filed 2018-11-07 | $362.00K derived: sum of 4 quarters · filed 2018-11-07 | |
| 2017-06-30 | $91.00K 10-Q · filed 2018-08-09 | $181.00K 10-Q · filed 2018-08-09 | $271.00K derived: sum of 3 quarters · filed 2018-08-09 | $357.00K derived: sum of 4 quarters · filed 2018-08-09 | |
| 2017-03-31 | $90.00K 10-Q · filed 2018-05-09 | $180.00K derived: sum of 2 quarters · filed 2018-05-09 | $266.00K derived: sum of 3 quarters · filed 2018-05-09 | $351.00K derived: sum of 4 quarters · filed 2018-05-09 | |
| 2016-12-31 | $90.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $176.00K derived: sum of 2 quarters · filed 2018-03-14 | $261.00K derived: sum of 3 quarters · filed 2018-03-14 | $346.00K 10-K · filed 2018-03-14 | |
| 2016-09-30 | $86.00K 10-Q · filed 2017-11-08 | $171.00K derived: sum of 2 quarters · filed 2017-11-08 | $256.00K 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | $85.00K 10-Q · filed 2017-08-09 | $170.00K 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | $6.00K 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |